Effect of sarpogrelate after endovascular treatment for femoropopliteal disease in patients treated with sarpogrelate

Effect of sarpogrelate after endovascular treatment for femoropopliteal disease in patients treated with sarpogrelate - ESPALIER

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006235

Enrollment

180

Registered

2011-10-01

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peripheral artery disease

Interventions

aspirin aspirin + sarpogrelate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Rutherford class 2 to 5 LEss than 0.9 of ABI More than 50% stenosis by visual estimate patients wtih procedure success

Exclusion criteria

Exclusion criteria: Patients with previous lower extremity bypass surgery, previous EVT in the femoropopliteal artery, acute onset limb ischemia, or severe lower extremity ischemic symptoms classified into Rutherford category 1 or 6

Design outcomes

Primary

Measure	Time frame
primary patency	—

Secondary

Measure	Time frame
secondary patency target lesion revascularization (TLR) major adverse cardiovascular events(MACE include death, non-fatal NI, stroke,revascularization, maojor amputtion)	—

Countries

Japan

Contacts

Public ContactYoshimitsu Soga

Kokura Memorial Hospital Cardiology

sogacchy@yahoo.co.jp093-511-2000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026